South Korea aims to use organoids in experiments instead of animals.

On July 15, 2024, Rep. Lim I-ja of the People Power Party introduced a bill to amend the ‘Act on the Registration and Evaluation of Chemical Substances’ (K-REACH). This bill aims to allow the use of organoids - artificial organs made from stem cells – in place of animals in experiments. The bill includes provisions for the development and verification of these methods, the establishment of verification and training centres, and the promotion of international cooperation with the OECD. 

Impact on the Biotechnology Industry 

The biotechnology industry is optimistic about the bill and expects it to boost the market for organoids, which are seen as the next generation of bio-industrial technology. The global organoid market is projected to grow significantly, from $1.42 billion in 2023 to $4.38 billion by 2028, with a CAGR of 25.2%. Key players in Korea include CHA Biotech, Cytogen, Gradient, Aligned, JW Shinyak, and T&R Biofab. 

Key Points: 

• Organoids as Animal Substitutes: The bill proposes the use of organoids in place of animals for testing. 

• International Standards: Establishes centres for verification and training to meet international standards. 

• Market Growth: Expected to significantly boost the organoid market, both domestically and globally. 

This bill is poised to create a new ecosystem for the high-tech chemical testing industry, fostering international cooperation and market growth.